Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both Hepatitis B and C strains independently

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 11, 2010, Pages 1763-1768

  Chen, Jing Yi ^a   Wang, Jing Houng ^b,c   Lin, Chih Yun ^b   Chen, Pao Fei ^b   Tseng, Po Lin ^b   Chen, Chien Hung ^b   Chang, Kuo Chin ^b   Tsai, Lin San ^d   Chen, Shu Chuan ^d   Lu, Sheng Nan ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d DEPARTMENT OF HEALTH   (Taiwan)

Author keywords

Cholesterol; Hepatitis B virus; Hepatitis C virus; Hyperlipidemia; Triglyceride

Indexed keywords

ALBUMIN; GLOBULIN; GLUCOSE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SCREENING; SENESCENCE; SEROPREVALENCE; SEX DIFFERENCE; TAIWAN; THROMBOCYTE COUNT;

EID: 78149268950     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06300.x     Document Type: Article

References (38)

1. World Health Organization. August 2008 revision date. Hepatitis B. World Health Organization Fact Sheet 204. Cited 16 Jan 2010. Available from URL:
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.
3. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J. Formos. Med. Assoc. 2007; 106: 148-55.
4. Lok AS. Chronic hepatitis B. N. Engl. J. Med. 2002; 346: 1682-3.
5. Anonymous. NIH consensus statement on management of hepatitis C: 2002. NIH Consens. State Sci. Statements 2002; 19: 1-46.
6. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000; 20: 1-16.
7. Lu SN, Chue PY, Chen HC et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J. Gastroenterol. Hepatol. 1997; 12: 547-50.
8. Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am. J. Trop. Med. Hyg. 2002; 66: 389-93.
9. Tsai MC, Kee KM, Chen YD et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J. Gastroenterol. Hepatol. 2007; 22: 92-8.
10. Wang JH, Lu SN, Wu JC et al. A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Trans. R. Soc. Trop. Med. Hyg. 1999; 93: 253-4.
11. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006; 45: 529-38.
12. Lu SN, Su WW, Yang SS et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int. J. Cancer. 2006; 119: 1946-52.
13. Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin. Liver Dis. 2004; 8: 403-18.
14. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J. Viral Hepat. 1997; 4: 9-28.
15. Congia M, Clemente MG, Dessi C et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24: 1338-41.
16. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35: 947-52.
17. Dai CY, Chuang WL, Ho CK et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J. Hepatol. 2008; 49: 9-16.
18. Siagris D, Christofidou M, Theocharis GJ et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J. Viral Hepat. 2006; 13: 56-61.
19. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin. Chim. Acta 1997; 261: 159-65.
20. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouille'res O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 2001; 34: 428-34.
21. Chang HY, Yeh WT, Chang YH, Tsai KS, Pan WH. Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993-1996). Chin. J. Physiol. 2002; 45: 187-97.
22. Monazahian M, Kippenberger S, Müller A et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med. Microbiol. Immunol. 2000; 188: 177-84.
23. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002; 16: 185-94.
24. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1999; 96: 12766-71.
25. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
26. Maggi G, Bottelli R, Gola D et al. Serum cholesterol and chronic hepatitis C. Ital. J. Gastroenterol. 1996; 28: 436-40.
27. Su TC, Lee YT, Cheng TJ, Chien HP, Wang JD. Chronic hepatitis B virus infection and dyslipidemia. J. Formos. Med. Assoc. 2004; 103: 286-91.
28. Chen Z, Keech A, Collins R et al. Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. BMJ 1993; 306: 890-4.
29. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J. Viral Hepat. 2007; 14: 147-52.
30. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
31. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 1999; 31: 9-16.
32. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sci. 2000; 45: 1929-34.
33. Angelico F, Del Ben M, Conti R et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003; 18: 588-94.
34. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment. Pharmacol. Ther. 2006; 23: 1055-65.
35. Lu SN, Wang JH, Liu SL et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107: 2212-22.
36. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
37. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
38. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-14.